UNCYUnicycive Therapeutics, Inc.

Sign up free

Market reactionShares fell 11% on Nov 2.

ChallengedLast material event Aug 12, 2026 · Updated Oct 21, 2026

FDA accepts OLC resubmission; March 25, 2027 decision target shifts focus to manufacturing

Unicycive is a clinical-stage company developing oxylanthanum carbonate (OLC), an oral phosphate binder for people with chronic kidney disease on dialysis; it is not approved.

Unicycive's investment case depends on OLC approval and a lower-pill-burden launch. FDA accepted the new-manufacturer resubmission, with a March 25, 2027 target action date. Prior rejections concerned the original manufacturer's deficiencies, not clinical safety or efficacy. Possible inspection of the new vendor remains a key uncertainty. Management expects cash runway into the second half of 2027, supporting launch preparation, while a securities class action adds legal uncertainty.

Thesis checklist

0 risks need attention

Select a row for evidence
FDA accepts the resubmission and approves OLCAwaiting evidenceNext: FDA's action on OLC and clarification of any new-vendor inspection requirement.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts until approval and launchAwaiting evidenceNext: Updated cash, launch spending and runway guidance in the next financial report.

Why it is in this state

The evidence, what would weaken it and the source filing

The securities class action does not disrupt the companyAwaiting evidenceNext: Court rulings or company disclosures clarifying financial exposure and business disruption.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

FDA decision on OLC with the new manufacturer

Tests: FDA accepts the resubmission and approves OLC

PDUFA target action date: March 25, 2027

Does FDA approve OLC using the new manufacturing package?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentRegulatory
+7.8%Aug 12, 2026

FDA accepts OLC resubmission; March 25, 2027 decision target shifts focus to manufacturing

ChallengedRegulatory
-39.1%Jun 30, 2026

OLC lands a second manufacturing CRL days after its PDUFA date; approvability on the science is intact, but a third submission now depends on CMO remediation

ChallengedRegulatory
-40.9%Jun 10, 2025

FDA identifies cGMP deficiencies at OLC CDMO subcontractor

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Hyperphosphatemia· chronic kidney disease on dialysis
OLC · 3 upcoming · 4 completed
PDUFA Decision
March 25, 2027
Commercial Launch
late 2025H1 2027
Regulatory Decision
TBD

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Unicycive Therapeutics (UNCY) investment thesis intact?
It is under pressure. Readouts currently rates the Unicycive Therapeutics Thesis Challenged. FDA accepts OLC resubmission; March 25, 2027 decision target shifts focus to manufacturing.
What is the next catalyst for Unicycive Therapeutics (UNCY)?
The next dated event is the FDA decision on OLC, on Mar 25, 2027, as stated by the company.
How long will Unicycive Therapeutics' cash last?
Unicycive Therapeutics has said its cash will fund operations into H2 2027 (guidance as of September 29, 2026).

Other companies we cover in these diseases

Disease areas: Kidney diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

2 peers tracked

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.